N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Primary: Time to Best Overall Response — 14 months
Phase 2 N=36 Effect of Intralymphatic Immunotherapy
Allergy · Immune Tolerance · Injection Site Discomfort
Primary: Change in cSMS (Combined Symptom and Medication Score) — 2.6; 2.3; 4.5 score on a scale
Phase 3 N=5 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
Phase 2 N=26 Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Phase 2 N=5 SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
Solid Tumor
Primary: Number of Patients With Improved Disease Control — 0; 0; 0; 0 Participants
Phase 2 N=56 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 4 N=280 Immunomodulation Following Transfusion
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
Phase 2 N=73 Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
Lung Cancer · Adenocarcinoma
Primary: Phase I: Recommend Phase II Dose (RPDII) — 1 Recommend Phase II Dose Level
Phase 2 N=33 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P — 0; 2; 0; 0 Participants
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 1 N=39 Immunotherapy of Stage III/IV Melanoma Patients
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
N/A N=12 The Differential Effects of 3 Different Immunosuppressive
Immunosuppression · Kidney Transplantation
Primary: CD4+CD25 High FOXP3+ Cell Levels in Mixed Lymphocyte Reactions (MLRs) of Renal Pre-transplant Recipients/Donors — 90; 85; 25; 50 Percentage of Control Cells
Phase 1 N=25 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Advanced Cancer
Primary: Treatment-related Adverse Events — 19; 103; 85 Number of Treatment-related Adverse Even
Phase 2 N=25 The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
Phase 2 N=58 Allergy Immunotherapy for the Reduction of Asthma
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
Phase 2 N=7 CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: CTL With Anti-CTLA4
Phase 2 N=20 UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
Advanced Solid Tumors · Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 300 mg
N/A N=20 Immunological Response After Shrimp Oral Immunotherapy Treatment
Allergy to Shrimp · Immunotherapy
Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
Phase 2 N=41 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
B-Cell Non-Hodgkin Lymphoma · Hematopoietic and Lymphoid Cell Neoplasm · Leukemia
Primary: Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant — 10; 2 Participants
Phase 2 N=20 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Neoplasm in the Lung · Salivary Gland Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 — 3; 1; 2; 6 Participants
Phase 2 N=12 Peginterferon and TIL Therapy for Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Adverse Events/Serious Adverse Events — 12; 12; 4 Participants
Phase 2 N=170 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants
Phase 2 N=59 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
Early Phase 1 N=16 Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Oral Squamous Cell Carcinoma
Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response — 9; 6 Participants
Phase 3 N=789 Study of Immunotherapy to Treat Advanced Prostate Cancer
Prostate Cancer
Primary: Overall Survival (OS) — 11.04; 10.02 months — p=0.0127
Phase 1 N=24 Pembrolizumab and Palliative Radiotherapy in Lung
Thoracic Tumours
Primary: Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 — 0; 0; 0; 0 Participants
N/A N=9 Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
Breast Cancer · Upper Extremity Lymphedema
Primary: Volume Changes as Measured by Perometry